REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
Back to dashboard
Company Information
About this company
Key people
Kenneth T. Mills
Chairman of the Board
Allan M. Fox
Independent Director
Alexandra Glucksmann
Independent Director
Curran M. Simpson
President, Chief Executive Officer, Director
Mitchell Chan
Chief Financial Officer, Executive Vice President, Treasurer
Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Olivier Danos
Executive Vice President, Chief Scientific Officer
Patrick J. Christmas
Executive Vice President, Chief Strategy and Legal Officer
Stephen Pakola
Executive Vice President, Chief Medical Officer
Daniel Tasse
Lead Independent Director
Gregory A. Ciongoli
Independent Director
Click to see more
Key facts
- Shares in issue66.01m
- EPICRGNX
- ISINUS75901B1070
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$457.14m
- Employees371
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.